Appendix 3Y - David Fenlon
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Elixinol Wellness Limited
ABN
34 621 479 794
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
David Fenlon
Date of last notice
12 December 2024
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
20 December 2024
No. of securities held prior to change
625,294 fully paid ordinary shares
996,307 performance rights
78,125 unlisted options exercisable at $0.16
per option, expiring 31 August 2025
78,125 unlisted options exercisable at $0.16
per option, expiring 23 November 2025
Class
(a) Fully paid ordinary shares
(b) Performance rights
Number acquired
(a) 938,087
(b) Nil
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Number disposed
(a) Nil
(b) 938,087
Value/Consideration
(a) Director Fee Rights issued in lieu of cash
consideration with a deemed issue price
of $0.04264 per Director Fee Right
(b) Nil cash consideration paid on vesting of
Director Fee Right
1,563,381 fully paid ordinary shares
58,220 performance rights
78,125 unlisted options exercisable at $0.16
per option, expiring 31 August 2025
78,125 unlisted options exercisable at $0.16
per option, expiring 23 November 2025
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buyback
Issue of fully paid ordinary shares upon
vesting of a portion of Director Fee Rights as
approved by Shareholders at the Company’s
Annual General Meeting held on 30 May
2024
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the N/A
trade to proceed during this period?
If prior written clearance was provided, on what date was N/A
this provided?
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Share your feedback
Discover